Stay updated with breaking news from Lynn Malec. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
“These autosomal diseases, from an inheritance standpoint, affect men and women equally, but because of their impact on the gynecological system and menses, women are often affected much more than men," hematologist Donna DiMichele, MD, explains.
A yearlong study of the newly approved half-life extender showed no evidence of factor VIII inhibitors.
Efaconescotog alfa defined a new therapy class by the US Food and Drug Administration (FDA) as the first and best-in-class high-sustained FVIII therapy.
Efanesoctocog alfa demonstrates promising results in new phase 3 data emphasizing the drug's potential to address unmet needs within the hemophilia community.
Once-weekly prophylaxis with a high-sustained factor VIII replacement therapy exhibited effective bleed protection for children with severe hemophilia A, according to the agent’s manufacturer.Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein (Altuviiio, Sanofi) is approved in the United States for routine prophylaxis and on-demand treatment to control bleeding episodes for